Kadmon Holdings Inc. (KDMN) |
|
9.5 0 (0%)
|
01-25 23:20 |
|
Open: |
9.49 |
Pre. Close: |
9.5 |
|
High:
|
9.495 |
Low:
|
9.48 |
|
Volume:
|
10,424,582 |
Market Cap:
|
1,696M |
|
|
|
|
Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include KD025, an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical trial for the treatment of chronic graft-versus-host and fibrotic diseases; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; ribavirin, a nucleoside Inhibitor to treat hepatitis; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. The company was founded in 2010 and is headquartered in New York, New York. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
9.522 - 9.569 |
9.569 - 9.607 |
|
Low:
|
9.347 - 9.413 |
9.413 - 9.465 |
|
Close:
|
9.409 - 9.507 |
9.507 - 9.587 |
|
Technical analysis |
as of: 2022-01-25 4:25:13 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 11.10 One year: 12.96 |
| Support: |
Support1: 9.49 Support2: 9.48 |
| Resistance: |
Resistance1: 9.50 Resistance2: 11.10 |
| Pivot: |
9.50 |
| Moving Average: |
MA(5): 9.50 MA(20): 9.50
MA(100): 8.43  MA(250): 5.89 |
| MACD: |
MACD(12,26): 0.03  Signal(9): 0.04 |
| Stochastic oscillator: |
%K(14,3): 100.00 %D(3): 100.00 |
| RSI: |
RSI(14): 72.90 |
| 52-week: |
High: 9.50 Low: 3.45 Change(%): 131.7 |
| Average Vol(K): |
3-Month: 9638 10-Days: 10425 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.KDMN has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to Kadmon Holdings Inc.'s normal range. The bands have been in this narrow range for 35 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Tue, 09 Nov 2021
Sanofi completes acquisition of Kadmon - Yahoo Finance
Tue, 19 Oct 2021
First Week of June 2022 Options Trading For Kadmon Holdings (KDMN) - Nasdaq
Thu, 07 Oct 2021
SHAREHOLDER ALERT: WeissLaw LLP Reminds XLRN, JMP, ECHO, and KDMN Shareholders About Its Ongoing Investigations - Yahoo Finance
Fri, 10 Sep 2021
KADMON HOLDINGS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kadmon Holdings, Inc. - KDMN - Business Wire
Wed, 08 Sep 2021
Should You Hold Kadmon Holdings Inc (KDMN) Stock Wednesday Morning? - InvestorsObserver
Wed, 08 Sep 2021
Why Kadmon Holdings Stock Is Rocketing Higher Today - Motley Fool
|
Financial Analysis |
| Growth |
|
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
 |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
|
| Shares Float (M) |
|
|
% Held by Insiders
|
|
|
% Held by Institutions
|
|
|
Shares Short (K)
|
|
|
Shares Short P. Month (K)
|
|
Stock Financials |
|
EPS
|
|
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
|
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
|
|
Return on Equity (ttm)
|
|
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
|
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
|
|
Levered Free Cash Flow (M)
|
|
Stock Valuations |
|
PE Ratio
|
1.#J |
|
PEG Ratio
|
|
|
Price to Book value
|
|
|
Price to Sales
|
|
|
Price to Cash Flow
|
|
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
